LIN › analyze
LIN · Analyze
Price at analysis: $461.62 (52-week range $387.78-548.20; down ~14.8% YTD 2026 and ~15.8% off the all-time high, underperforming the Dow's +11.4%). Sector: Basic Materials / Specialty Chemicals (mapped here to Industrials for portfolio-sleeve purposes). Employees 64,649. This is a sleeve-vacancy nomination for 📈 Income-Yield Tomorrow.
Knowledge-base check: kb.py find LIN and kb.py find "industrial gas" returned no live
notes or prior reports on this name — first file on LIN. No LIN-specific pitfalls exist yet, but
the general pitfall pitfall-vendor-forward-eps-is-the-wrong-fiscal-year fired on this name (see
Valuation) and is worth flagging back to the KB layer.
1. General Health (Fundamentals)
| Metric | 2022 | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|---|
| Revenue | $33.36B | $32.85B | $33.01B | $33.99B | ~flat, 3yr CAGR +0.6% |
| Gross margin | - | 46.8% | 48.1% | 48.8% | expanding |
| Operating margin | - | 24.7% | 26.0% | 27.2% | expanding |
| Net income | $4.15B | $6.20B | $6.57B | $6.90B | 3yr CAGR +18.5% |
| OCF | $8.86B | $9.30B | $9.42B | $10.35B | 3yr CAGR +5.3% |
| Capex | $3.17B | $3.79B | $4.50B | $5.26B | +66% in 3yr |
| FCF (OCF-capex) | $5.69B | $5.52B | $4.93B | $5.09B | 3yr CAGR -3.7% |
| Buybacks | $5.17B | $3.96B | $4.48B | $4.60B | steady |
| Dividends paid | $2.34B | $2.48B | $2.65B | $2.81B | steady growth |
| Shares (diluted) | 504.0M | 492.3M | 482.1M | 472.9M | 3yr CAGR -2.1% |
| Debt/Assets | - | - | 28.2% | 32.3% | rising |
| Net debt/EBITDA | - | - | 1.35x | 1.73x | rising |
FCF CAGR is negative, and that needs unpacking rather than flagging red. Revenue is essentially flat by design — management has been trading low-return merchant volume for margin ("value over volume"), which is why gross and operating margin both expanded while the top line didn't move. Net income and OCF both grew comfortably. The FCF decline is entirely a capex story: capex grew 66% in three years against a backlog that just hit a record $8.1B (electronics-led — a $1B US semiconductor win plus an $800M Taiwan JV for advanced-node fabs) and that management says will still show "an eight-handle" at year-end even after $1.3B of 2026 project startups convert to revenue. This is contracted, take-or-pay-backed growth capex, not discretionary spend or a sign of deteriorating unit economics — but it is real cash out the door today for cash flow that shows up over the 2027-2029 window, and it is the correct explanation for why a "quality compounder" screen shows a shrinking FCF line.
The capex cycle is being partly debt-funded, and that is the one real balance-sheet flag. FY2025 uses of cash (capex $5.26B + buybacks $4.60B + dividends $2.81B + bolt-on M&A $0.41B = $13.2B) exceeded OCF ($10.35B) by ~$2.9B, funded by net new debt issuance. Net debt/EBITDA moved from 1.35x to 1.73x in one year. Leverage is still comfortably investment-grade — S&P A / Moody's A2, stable outlook, and EBITDA covers interest expense ~27x — but the trend line is worth watching if the capex cycle runs longer than the backlog conversion schedule implies.
Shares outstanding fell steadily (-2.1% 3yr CAGR) on a disciplined buyback program — a genuine per-share tailwind layered on top of the earnings growth.
FCF/share: $10.76 (2025, OCF-capex basis). Revenue/share: $71.86-76.20 (fin.py vs. Yahoo basis differ slightly on trailing-vs-fiscal-year revenue; not material). ROIC 10.6%, ROE 18.1%, ROA 8.3% — solid for a capital-intensive business, not spectacular in isolation, but the right read for an industrial-gas utility-like model is the stability and rise of these numbers (ROIC 10.6% up from 10.4% five years ago on a much larger capital base) rather than the absolute level.
§1 health-bar answer: Green with one watch-item. Margins, ROIC, buybacks, and net income are all strong and improving. The flag is the capex-driven FCF compression and the debt-funded gap between OCF and total cash uses — not a decaying business, but not a free lunch either.
2. Moat & Competitive Advantage
Structure: a three-player global oligopoly. Linde, Air Liquide, and Air Products control the large majority of global industrial-gas supply following Linde's 2018 merger with Praxair (cleared in the US, EU, and China only after divestitures — Messer Group and Matheson Tri-Gas were spun out to satisfy antitrust). Regional players (Air Water, Messer, SIAD) compete at the margins but none has the global density to contest on-site or large-project bids.
On-site plants carry the strongest moat in the portfolio-sleeve candidate set. These are built adjacent to (or piped directly into) a single large customer under 15-20yr take-or-pay contracts — the customer commits to a minimum volume regardless of usage. Once built, there is effectively zero probability of re-competing the asset within the contract term: a rival would have to build a duplicate plant next to an already-served customer to contest it, which the economics never justify. This is closer to a regulated-utility moat than a normal industrial company's.
Density economics compound regionally. The more plants and pipeline the incumbent has in a given geography, the lower its marginal cost to serve the next customer in that geography — a genuine scale/network effect that a new entrant cannot buy its way into without years of uneconomic buildout.
Merchant/packaged gas (cylinders, bulk liquid delivery) is the softer part of the moat — relationship- and logistics-based switching costs, real but not structural. This is also where Linde has been deliberately shedding low-return volume, which shows up as the flat top line above.
Growth vector — electronics/AI capex. Electronics is now the fastest-growing end market: record backlog, the $1B US semiconductor win, and the $800M Taiwan joint venture for advanced-node fab and AI-hardware packaging capacity. This is high-return, contracted growth riding the same AI-buildout wave as the data-center capex story, without the pricing risk of selling into it directly.
Hydrogen/clean-energy optionality is real but not yet an earnings driver. Linde is a leading builder of hydrogen production and liquefaction infrastructure, but monetization pace is policy-dependent (US 45V credit uncertainty, EU Hydrogen Bank timelines) — treat this as a long-duration call option embedded in the stock, not a line item to underwrite today.
The one real soft spot: Lincare. The US home-respiratory/oxygen healthcare segment (acquired legacy business, sits in the Americas segment) is absorbing cost inflation that diluted pricing/productivity gains enough to cost the whole company 60bps of adjusted operating margin in Q2 2026. It's a small piece of the overall business but it is the one place cracking against an otherwise expanding-margin story, and it's exactly the kind of thing a rival moat narrative would gloss over.
Adversarial stress-test: a well-funded rival cannot contest an existing on-site contract or easily replicate regional density; the real competitive contest happens at the bid stage for new projects, where Air Liquide and Air Products both compete hard on price and could compress returns on future project wins even though installed contracts are untouchable. Evergreen assessment: yes — industrial gas is a permanent input to healthcare, chemicals, metals, food, and now electronics; the business model doesn't face a plausible technological obsolescence path within a 10-year horizon. Moat rating: very durable, arguably the strongest moat of any name currently being evaluated for this sleeve.
3. Valuation
A vendor-forward-P/E trap fired on this name — corrected below. Yahoo's forwardPE of
23.61x prices forwardEps $19.556, which cross-checks to FY2027 consensus, not FY2026.
Yahoo's own epsCurrentYear/priceEpsCurrentYear fields carry the correct current-year read:
$17.87 / 25.83x — and that ties almost exactly to the company's own reaffirmed FY2026 adjusted
EPS guide of $17.70-17.90 (raised at the low end after Q2). The commonly-quoted "23.6x
forward" understates Linde's true current-year multiple by roughly two turns — the real number
is ~25.9x on FY2026 guidance, not 23.6x. This report's fair value and trim below are built on
the guided FY2026 EPS, not the vendor's mislabeled field. (Flagging for the Playbook: this is the
same failure mode already logged in pitfall-vendor-forward-eps-is-the-wrong-fiscal-year, now
observed on LIN — orchestrator should consider appending it to that note's ticker list.)
| Multiple | Basis | Value |
|---|---|---|
| Trailing P/E | FY2025 actual EPS $15.33 | 30.1x |
| True current-FY P/E | FY2026 guide midpoint $17.80 | 25.9x |
| Vendor "forward P/E" (mislabeled) | FY2027 consensus $19.56 | 23.6x (do not use as "forward") |
| PEG | — | 1.81-1.85 |
| P/B | BVPS $84.78 | 5.45x |
| EV/EBITDA | — | 17.2x |
Graham's Intrinsic Value: √(22.5 × 15.33 × 84.78) = $171 vs. spot $461.62. Graham says dramatically overvalued — but this is the wrong tool for a 18% ROE, >5x book-value business; the formula is built for asset-backed value plays and structurally cannot accommodate a high-return capital compounder. Weighted near zero per the framework's own conditional-use rule; noted for completeness, not treated as signal.
Dividend Yield Theory: current yield 1.37% vs. its own 5-year average of 1.30% — essentially in line with its own history, arguably a touch rich relative to that band. No buy signal from DYT; the stock is not cheap by its own yield history despite the 14.8% YTD drawdown.
Bogle's Expected Return: yield 1.4% + guided EPS growth 8-9% ± multiple change. With the multiple held flat, expected return runs ~9.5-10.5%/yr; if the current-FY multiple mean-reverts even modestly toward the low-24x area it has traded at across the cycle, the total-return estimate compresses toward high single digits. A solid, unspectacular compounder return — not a value-re-rating setup.
Two-stage DDM (assumptions stated explicitly): D0 = $6.40 current run-rate. Stage 1: 8%/yr dividend growth for 10 years (matches the 3-10yr actual dividend CAGR of 7.8-8.9%). Terminal growth 4%. Discount rate 8% (justified by beta 0.73 and A/A2 credit quality). Result: PV ≈ $220-230. Loosening the discount rate to 7.5% with the same terminal growth lifts it to ~$270- 290. Every reasonable assumption set here lands well below the $461.62 spot price — this model says the stock's expected return is coming from multiple-and-growth expectations embedded in the price, not from a dividend stream that clears a normal required return with room to spare. This is a low-yielder, so the result shouldn't be over-read as "wildly overvalued," but it confirms there is no DDM-based cushion.
Fair value range: applying a normalized 23-27x multiple — the more realistic part of its own historical band, not the ~35x figure some vendors quote for the "5yr average" (which looks distorted by a low-earnings year in the denominator) — to the company's own guided FY2026 EPS ($17.80): FV $410-480, central ~$445. Spot $461.62 sits in the upper-middle of this band.
Sell-side context, held at arm's length: mean analyst target $544.54 (24 analysts, Buy consensus, 1.70 recommendation mean) implies ~18% upside — but sell-side targets on quality compounders skew optimistic on trend-following, and shouldn't be treated as a valuation anchor independent of the above models.
Margin-of-safety verdict — answering the brief directly: there is effectively none at $461.62. The stock sits inside a rationally derived fair-value band, but near its top; DYT says it's not cheap by its own yield history; DDM finds no cushion at a normal discount rate; and the market's own recent behavior corroborates this — Q2 2026 beat on sales and EPS but the stock fell ~5-6% that day because the FY26 guide raise was judged too small and Lincare margin softened. The bar is priced high enough that in-line-to-good results are triggering sell-offs, which is exactly what "no margin of safety" looks like in practice, even during a 14.8% YTD drawdown.
4. Dividend-Grower Overlay
- 34 consecutive years of dividend increases — a recognized Dividend Aristocrat, on pace toward Dividend King status (50 years) in roughly a decade and a half.
- Dividend CAGR: 1yr 7.3% · 3yr 8.2% · 5yr 8.9% · 10yr 7.8% — steady high-single-digit compounding, not accelerating or decelerating meaningfully.
- EPS payout ratio: ~39-40% — well covered on a GAAP-earnings basis, plenty of room to keep raising ahead of FCF if needed.
- FCF payout (cash basis): $2.81B dividends / $5.09B FCF (OCF-capex) = ~55% — meaningfully tighter than the EPS-basis payout once the capex cycle is netted out. Still comfortably covered, but the two payout ratios telling different stories is worth naming rather than only quoting the flattering one.
- Current yield 1.37% is genuinely low for an "income" name — this is a "yield tomorrow" thesis entirely on the strength of the dividend-growth rate and the safety of the base, not a name that contributes meaningful current income to a portfolio today.
5. Sentiment
- Stock down ~14.8% YTD 2026 and ~15.8% off its all-time high ($548.20), underperforming the Dow (+11.4%) and S&P 500 over the same window.
- Q2 2026 (reported early Aug): record sales $9.3B (+9% YoY), adjusted EPS $4.50 (+10% YoY) — a beat on both lines — but shares fell ~5-6% on the print because adjusted operating margin contracted 60bps to 29.5% (Lincare/Americas cost inflation) and the FY26 EPS guide was only raised at the bottom end ($17.60→$17.70, top held at $17.90).
- Backlog: record $8.1B, electronics-led ($1B US semiconductor win, $800M Taiwan JV for advanced-node fabs) — the growth engine looks intact, arguably strengthening on the AI-capex wave.
- Ownership: ~88-89% institutional, <0.3% insider (typical for a mega-cap, not a red flag). One VP-level insider sale (~$4.5M, ~30% of a small personal stake) noted — immaterial.
- Analyst consensus: strongly Buy (21 buy / 5 hold / 1 sell per one aggregator), mean target $544-548 — the Street is treating the drawdown as a buying opportunity. Named tension: this sits in some contrast with the DYT/DDM read above that there is no real margin of safety; sell-side momentum bullishness and the framework's own valuation discipline disagree here, and that disagreement should be carried forward rather than papered over.
- No new antitrust, regulatory, or competitive-structure risk identified beyond the historical 2018 Linde-Praxair merger remedies, which are long since settled and priced in.
6. Synthesis & Verdict
Answering the brief's four questions directly:
(1) §1 health bar: Green with one watch-item. Margins, ROIC, and buyback discipline are all strong and improving; the flag is capex-driven FCF compression (contracted, not organic decay) funded partly by rising leverage (net debt/EBITDA 1.35x→1.73x in one year, still comfortably A/A2-rated).
(2) Buy zone or watch: WATCH. Fair value $410-480 (central ~$445) against a $461.62 spot — sitting at the upper-middle of a band that already used a realistic (not inflated) historical multiple. No model here — Graham excluded, DYT, DDM, or the plain "beat-but-sold-off" market behavior — supports calling this a bargain today. Entry zone $400-430 (roughly a 7-13% pullback from spot, close to but not requiring a retest of the 52-week low $387.78). Trim 28x FY26 (≈$498 on the $17.80 guide midpoint — stated explicitly on the FY26 guided-EPS basis to avoid re-inheriting the forward-year mislabel documented above).
(3) Does LIN beat the weakest Yield-Tomorrow members, ZTS and HLNE (both 5.5)? Yes, on business quality and safety — not decisively, and not on price. LIN's moat is the cleanest of the three (a true oligopoly with 15-20yr take-or-pay contracts, versus ZTS's patent-cliff exposure and negative organic growth, or HLNE's contested FRE-definition restatement). LIN's dividend record (34yr streak) is longer than either, and its balance sheet (A/A2) carries no earnings-quality controversy. But none of the three currently offers real valuation margin of safety — ZTS sits at its own fair-value center, HLNE trades 12-16% above its zone, and LIN sits at the upper-middle of its band — and LIN's current yield (1.37%) is the thinnest of the group. The edge is business quality, not opportunity.
(4) Proposed conviction: 6.0 — half a point above ZTS/HLNE, reflecting superior and cleaner moat quality with zero identified accounting or earnings-quality red flags, offset by a valuation that offers no cushion and a current yield too low to carry the "income" half of the thesis on its own. This is a name to want in the sleeve at a better price, not to chase at this one.
Biggest risk: the market has already shown its hand once — a genuine beat-and-raise (Q2 2026) still sold off 5-6% because the guide raise and margin trend weren't good enough for a stock priced at ~26x current-year earnings. At this valuation, LIN needs the electronics-led backlog to convert into FCF (not just revenue) on schedule and the Lincare/Americas margin drag to stabilize; a second consecutive quarter of margin disappointment or backlog-conversion slippage, layered on the already-rising leverage, is what would turn "no margin of safety" into an actual re-rating down, not just a paper one.